203 related articles for article (PubMed ID: 29346833)
1. Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.
Tan EH; Lim WT; Ahn MJ; Ng QS; Ahn JS; Shao-Weng Tan D; Sun JM; Han M; Payumo FC; McKee K; Yin W; Credi M; Agarwal S; Jac J; Park K
Clin Pharmacol Drug Dev; 2018 Jun; 7(5):532-542. PubMed ID: 29346833
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Wu YL; Zhang L; Kim DW; Liu X; Lee DH; Yang JC; Ahn MJ; Vansteenkiste JF; Su WC; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan DSW
J Clin Oncol; 2018 Nov; 36(31):3101-3109. PubMed ID: 30156984
[TBL] [Abstract][Full Text] [Related]
3. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
5. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Yang JJ; Fang J; Shu YQ; Chang JH; Chen GY; He JX; Li W; Liu XQ; Yang N; Zhou C; Huang JA; Frigault MM; Hartmaier R; Ahmed GF; Egile C; Morgan S; Verheijen RB; Mellemgaard A; Yang L; Wu YL
Invest New Drugs; 2021 Apr; 39(2):477-487. PubMed ID: 33052556
[TBL] [Abstract][Full Text] [Related]
6. A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma.
Mok TS; Geater SL; Su WC; Tan EH; Yang JC; Chang GC; Han M; Komarnitsky P; Payumo F; Garrus JE; Close S; Park K
J Thorac Oncol; 2016 Oct; 11(10):1736-44. PubMed ID: 27448761
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
Creelan BC; Yeh TC; Kim SW; Nogami N; Kim DW; Chow LQM; Kanda S; Taylor R; Tang W; Tang M; Angell HK; Roudier MP; Marotti M; Gibbons DL
Br J Cancer; 2021 Jan; 124(2):383-390. PubMed ID: 33012782
[TBL] [Abstract][Full Text] [Related]
8. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M
Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.
Su VY; Yang KY; Huang TY; Hsu CC; Chen YM; Yen JC; Chou YC; Chang YL; He CH
Sci Rep; 2020 Sep; 10(1):14965. PubMed ID: 32917914
[TBL] [Abstract][Full Text] [Related]
11. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
Tarhini AA; Rafique I; Floros T; Tran P; Gooding WE; Villaruz LC; Burns TF; Friedland DM; Petro DP; Farooqui M; Gomez-Garcia J; Gaither-Davis A; Dacic S; Argiris A; Socinski MA; Stabile LP; Siegfried JM
Cancer; 2017 Aug; 123(15):2936-2944. PubMed ID: 28472537
[TBL] [Abstract][Full Text] [Related]
12. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R
Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629
[TBL] [Abstract][Full Text] [Related]
13. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.
Yang JC; Gadgeel SM; Sequist LV; Wu CL; Papadimitrakopoulou VA; Su WC; Fiore J; Saraf S; Raftopoulos H; Patnaik A
J Thorac Oncol; 2019 Mar; 14(3):553-559. PubMed ID: 30529597
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Hosomi Y; Morita S; Sugawara S; Kato T; Fukuhara T; Gemma A; Takahashi K; Fujita Y; Harada T; Minato K; Takamura K; Hagiwara K; Kobayashi K; Nukiwa T; Inoue A;
J Clin Oncol; 2020 Jan; 38(2):115-123. PubMed ID: 31682542
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in
Noronha V; Patil VM; Joshi A; Menon N; Chougule A; Mahajan A; Janu A; Purandare N; Kumar R; More S; Goud S; Kadam N; Daware N; Bhattacharjee A; Shah S; Yadav A; Trivedi V; Behel V; Dutt A; Banavali SD; Prabhash K
J Clin Oncol; 2020 Jan; 38(2):124-136. PubMed ID: 31411950
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.
Takeuchi S; Hase T; Shimizu S; Ando M; Hata A; Murakami H; Kawakami T; Nagase K; Yoshimura K; Fujiwara T; Tanimoto A; Nishiyama A; Arai S; Fukuda K; Katakami N; Takahashi T; Hasegawa Y; Ko TK; Ong ST; Yano S
Cancer Sci; 2020 Feb; 111(2):561-570. PubMed ID: 31782583
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]